What is optimal first-line treatment of unresectable or advanced BRAF-mutant melanoma?

MA BRAF-mutant melanomas tend to develop in preexisting moles. They also tend to affect younger patients; 70% to 80% of the patients who are younger than 30 years when melanoma develops have BRAF-mutant tumors. Conversely, BRAF–wild-type melanomas tend to develop in heavily sun-damaged skin. They tend to affect older patients, especially those aged 70 years and older. Most acral and nearly all mucosal melanomas are BRAF– wild-type. As far as prognosis is concerned, acral melanomas and mucosal melanomas tend to have a worse prognosis than other melanomas, so patients with BRAF–wild-type melanoma may have a worse outcome. Among patients with BRAF–wild-type melanoma, those with NRASmutant melanoma have the worst prognosis. H&O Which agents are approved for the firstline treatment of patients with BRAF-mutant melanoma?